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SHORT ABSTRACT TEXT (less than 200 words) 
 
Bone remodeling is a process essential for maintaining bone strength and integrity, 
requiring actions of bone resorbing osteoclasts and bone forming osteoblasts. The 
actions of these cells are highly regulated through cellular interactions between each 
other and with other cells in the local microenvironment. Cells of the immune system, 
which are often in close proximity to bone and share common progenitors and 
control mechanisms with bone cells, are emerging as an important theme in bone 
research.  
 
This study explore the role of interleukin-33 (IL-33), a Th2 stimulator, acting via its 
receptor, ST2L, and is related to IL-1 and IL-18, both influence bone metabolism. We 
found  a novel role of IL-33 as an inhibitor of  osteoclast formation via several 
mechanisms, mediated by T cells, osteoblasts and mature macrophages. IL-33, like 
IL-23, also induces GM-CSF secretion, which mediates most of its inhibitory action, 
increasing dendritic cell formation from hematopoietic progenitors probably at the 
expense of osteoclast formation. Furthermore, IL-33, enhanced osteoblast matrix 
mineralisation and suppression of osteocytic bone formation inhibitor, SOST 
(sclerostin), features displayed by anabolic cytokines like oncostatin M (OSM). 
Indeed, OSM increased IL-33 mRNA levels as did PTH another bone anabolic agent, 
These findings indicated IL-33 has important influences on bone metabolism. 
 
 
LONG ABSTRACT TEXT (less than 400 words) 
 
Bone remodeling is a process essential for maintaining bone strength and integrity, 
requiring actions of bone resorbing osteoclasts and bone forming osteoblasts. 
Osteoclasts derive from hematopoietic cells that also form macrophages and 
dendritic cells, while osteoblasts derive from osteoprogenitors of mesenchymal 
origin. The actions of these cells are highly regulated through cellular interactions 
between each other and with other cells in the local microenvironment. Cells of the 
immune system, which are often in close proximity to bone and share common 
progenitors and control mechanisms with bone cells, are emerging as an important 
theme in bone research.  
 
This study explore the role of a novel protein, interleukin-33 (IL-33), a Th2 stimulator, 
acting via its receptor, ST2L, related to IL-1 and IL-18. IL-18 in particular inhibits 
osteoclast formation and contributes to PTH bone anabolic actions. Immunostaining 
indicated IL-33 expression in osteoblasts in mouse bone and IL-33 mRNA 
expression in cultured calvarial osteoblasts, which was elevated by treatment with 
the bone anabolic factors oncostatin M and PTH. IL-33 treatment strongly inhibited 
osteoclast formation in bone marrow and spleen cell cultures but had no effect on 
osteoclast formation in receptor activator of nuclear factor-κB ligand/macrophage 
colony-stimulating factor-treated bone marrow macrophage (BMM) or RAW264.7 
cultures, suggesting a lack of direct action on immature osteoclast progenitors. 
However, osteoclast formation from BMM was inhibited by IL-33 in the presence of 
osteoblasts, T cells, or mature macrophages, suggesting these cell types may 
mediate some actions of IL-33. In bone marrow cultures, IL-33 induced mRNA 
expression of granulocyte macrophage colony-stimulating factor, IL-4, IL-13, and IL-
10; osteoclast inhibitory actions of IL-33 were rescued only by combined antibody 
ablation of these factors. In contrast to osteoclasts, IL-33 promoted matrix mineral 
deposition by long-term ascorbate treated primary osteoblasts and reduced 
sclerostin mRNA levels in such cultures after 6 and 24 h of treatment; sclerostin 
mRNA was also suppressed in IL-33-treated calvarial organ cultures, features 
displayed by anabolic cytokines like oncostatin M (OSM). Indeed, OSM increased IL-
33 mRNA levels as did PTH another bone anabolic agent. In summary, IL-33 inhibits 
osteoclast formation through at least three separate mechanisms and also stimulates 
osteoblastic function in vitro. Thus, autocrine and paracrine actions of osteoblast IL-
33 may influence bone metabolism.  
 
